UNITED THERAPEUTICS CORP
UTHRNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $455.63 β $614.23
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 42.9M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- $3.18B
- Last Q Revenue
- $833M
- P/E Ratio
- 18.7
- P/S Ratio
- 7.2x
- EPS (TTM)
- $26.51
- Dividend Yield
- β
- Dilution (1yr)
- β1.6%
UNITED THERAPEUTICS CORP
UTHRAbout UNITED THERAPEUTICS CORP
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidneyβ’ in Patients with End-Stage Renal Disease
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of t

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,627,990.00 in Stock
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $

Commonwealth Equity Services LLC Purchases 1,695 Shares of United Therapeutics Corporation $UTHR
Commonwealth Equity Services LLC lifted its position in United Therapeutics Corporation (NASDAQ: UTHR) by 32.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory

SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).